Pfizer signs licensing deal worth about $6 billion with China’s 3SBio for cancer drug
U.S. drugmaker Pfizer said on Monday it has signed a licensing agreement worth about $6 billion with Chinese biopharmaceutical company 3SBio Inc for the development, manufacturing and commercialization of a drug which could be used to treat certain types of cancer and tumors.